DocumentRX-8245
Issued
Read3 min

Isomorphic Labs signs Merck for AI-designed oncology drug two days after $5B raise

Two days after a $5B Series C, Isomorphic Labs signed Merck to design small molecules against one oncology target with its IsoDDE engine. Merck takes development, manufacturing and marketing.

TAG E-6328 · 501 words on the filing

Isomorphic Labs adds Merck as an oncology partner after $5 billion raise
Isomorphic Labs adds Merck as an oncology partner after $5 billion raiseelliepeek / pixabay

Summary of findings

  • Isomorphic Labs signed Merck two days after a $5 billion Series C; a $2.1 billion Series B closed in May.
  • IsoDDE more than doubles AlphaFold 3 accuracy on the hardest Runs N' Poses protein-ligand cases, per company benchmarking.
  • Fourth pharma partner after Lilly (2024), Novartis (2024, expanded February 2025) and J&J (January).
  • First clinical trial target set for end of 2026, per CEO Demis Hassabis.
  • Only about 2% of $29.5 billion in 2025 top-20 pharma AI deal headline value was paid upfront, per McKinsey.

Isomorphic Labs has signed Merck as its fourth pharmaceutical partner, two days after closing a $5 billion Series C. The Alphabet spinoff will deploy its IsoDDE drug-design engine against a single oncology target, using selected Merck datasets to generate small-molecule candidates.

The deal caps a defining stretch for the company. Isomorphic signed Johnson & Johnson in January as its third partner, after Eli Lilly and Novartis, and CEO Demis Hassabis, Ph.D., moved the company's first clinical trial target to the end of 2026. In May, Thrive Capital led a $2.1 billion Series B. The Series C arrives roughly six months later, on top of positive preclinical results in oncology and immunology.

What does each side contribute?

Isomorphic will run predictions in IsoDDE and deliver molecular designs. Merck, known as MSD outside the U.S. and Canada, will run preclinical and clinical development, then manufacture and market any resulting products. In short, Isomorphic supplies the computation and Merck carries the molecules through the clinic.

George Addona, head of discovery, preclinical development and translational medicine at Merck Research Laboratories, framed the collaboration around execution. "The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," Addona said.

The partnership structure follows a familiar pattern. Isomorphic receives an upfront payment and stands to earn milestone payments plus tiered royalties on net sales. It can also co-fund development in exchange for higher royalties. McKinsey analysis found that in the top 20 drugmakers' 2025 AI drug discovery deals, only about 2% of $29.5 billion in headline value was paid up front.

How strong is the underlying engine?

Isomorphic unveiled IsoDDE in February as a unified computational drug-design system the company says goes beyond AlphaFold 3. It predicts how strongly a drug binds to its target and the structure of the resulting complex.

The company's own benchmarking claims more than double the accuracy of AlphaFold 3 on the hardest protein-ligand cases in the Runs N' Poses benchmark. AlphaFold 3 itself was a joint development between Isomorphic and Google DeepMind, so the newer engine is measured against the company's own prior art rather than an outside baseline.

How does this fit the partnership record?

Isomorphic began working with Lilly and Novartis in January 2024 on small molecules for multiple targets. Novartis expanded the arrangement in February 2025, adding up to three research programs. The J&J deal covers multiple targets and spans both small molecules and biologics, marking the company's broadest collaboration to date.

The Merck arrangement is narrower by design: one oncology target, one modality. Takeaway: the deal tests IsoDDE's design claims inside a top-tier oncology pipeline with defined commercial terms.

The Series C will also fund internal programs. Isomorphic President Max Jaderberg described those assets on Nov. 2 as "deep in pre-clinical development" in oncology and immunology. Takeaway: Isomorphic is now financing both its platform partnerships and its own pipeline in parallel.

via blog.google (Original)

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering companies, deals and strategy in global pharmaceutical industry at PharmInsider.

11 articles

Linked filings

  1. K-4629
  2. E-6700
  3. T-6577
  4. E-9238
  5. V-5496

« Previous filingNext filing »